Avalanche Biotechnologies to Present at Upcoming Scientific Meetings
ARVO 2015 Annual Meeting
Oral Presentation:
One-Year Analysis of sFlt-1 and VEGF Proteins and Immunological Markers in the Bodily Fluids of Subjects Participating in the Phase I rAAV.sFlt-1 Trial
Presenter:
Date/Time:
Poster Presentations:
Neuroprotective Effect of AAV-Mediated Cell-Specific Expression of GDNF in Müller Glial Cells Versus Retinal Ganglion Cells in a Murine Model of Glaucoma
Presenter:
Date/Time:
Presenter: Szilárd Kiss, MD,
Date/Time:
About
Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit www.avalanchebiotech.com.
CONTACT: Investor ContactLauren Glaser (650) 656-9347 lauren@avalanchebiotech.com Media ContactCarolyn Wang (415) 946-1065 cwang@w2ogroup.com